Biggest News Aggregation in the World
๐Ÿ“ฐ Leukemia News

Page 203 - Leukemia News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Leukemia. Real-time updates on events, politics, business and more.

Dental School Researcher Gets Approval to Begin Clinical Trials for Cancer Therapy

Rutgers University Treatment Uses Protein found in Oral Bacterium A company founded by Rutgers School of Dental Medicine researcher Scott Kachlany received U.S. Food and Drug Administration (FDA) approval to begin a phase I clinical trial to treat cancer patients with a therapy based on Kachlanyโ€™s discovery that a protein produced by an oral bacterium can kill leukemia and lymphoma cells. The approval clears the way for Kachlanyโ€™s company, Actinobac Biomed, to begin the trial in patients wh...
New Jersey United States Scott Kachlany Actinobac Biomed Rutgers Cancer Institute Of New Jersey Rutgers School Of Dental Medicine

Aptevo Therapeutics Announces Expansion Phase of Lead Anti-Leukemia Drug APVO436 in Adult Patients with Acute Myeloid Leukemia

(0) Initiates Multi-Center, Multi-Arm Trial Using Active Dose Identified in the Dose Escalation Phase of the Trial SEATTLE, WA / ACCESSWIRE / May 27, 2021 / Aptevo Therapeutics Inc. ("Aptevo") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR TM and ADAPTIR-FLEX TM platform technologies today announced that the company has initiated the expansion phase of lead anti-leukemia drug candidate, APVO436, in ...
United States Fatih Uckun Justin Watts Marvin White Exchange Commission Aptevo Therapeutics Inc

Aptevo Therapeutics Reports Positive Phase 1 Clinical Data for Its Lead Leukemia Drug Candidate APVO436 in Adults With Relapsed Acute Myeloid Leukemia

Dose Escalation Study of APVO436 Shows Favorable Safety Profile and No Severe Neutropenia, a Potentially Life-threatening Side Effect, Reported in a Significant Number of Patients Receiving CD123-Targeting
United States Jane Gross Fatih Uckun Marvin White Exchange Commission Aptevo Therapeutics Inc

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News โ†’

FOXNEWS Fox News at Night With Shannon Bream June 4, 2024 04:53:00

Close to litigation if not there. >> these cases are in the courts. the number one cases through the pandemic have been employment cases. and just piggybacking on what he said, when his work stopped when he worked from home? that is the case is that we are seeing. the on the clock, off the clock. my concern is -- and i know that the biden administration is pushing some things around this -- is this might become the trial lawyers for lee facts with the type of lawsuits that we are going to see co...
Employment Cases Trial Lawyers Spoon Rights Dream Becoming The World Ups Driver Living Room

Detailed text transcripts for TV channel - CNN - 20210523:23:48:00

Brothers over this past year and a half, and i wouldnt trade that for anything. โ™ช >> quarantine was nothing new for kristen. in august 2019 kristen was diagnosed with leukemia and spent the next eight months in the hospital. >> i wore masks before they were cool. i wash my hands way more than the average person. and i kept everything clean. โ™ช >> kristins now cancer-free and recently receive someday more welcomed news. >> when i got the news that i was valedictorian, it was like a giant weigh...
Brother S Sat Trade August 2019 Gota Brand New Lease On Life Everything Number One

Incyte: Positive Primary Analysis from the Phase 2 OPTIC Study of Ponatinib (Iclusig) in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) to be Presented at the 2021 ASCO Annual Meeting

Incyte: Positive Primary Analysis from the Phase 2 OPTIC Study of Ponatinib (Iclusig) in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) to be Presented at the 2021 ASCO Annual Meeting Incyte (Nasdaq:INCY) today announced that data from the primary analysis of the Phase 2 OPTIC ( Optimizing In CML) trial will be presented during an oral session (Abstract #7000) at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, held virtually June 4-8, 2021. The OPTIC trial an ongoing, r...
United States United Kingdom Rachael Remaly Franco Luca Marini Istituto Romagnolo Gianantonio Rosti

Blocking TGFβ1 could improve hematopoiesis in AML patients, indicates study

Bone marrow failure due to acute myeloid leukemia (AML) is a significant factor behind the disease's high rate of morbidity and mortality. Previous studies in mice suggest that AML cells inhibit healthy hematopoietic (blood) stem and progenitor cells (HSPC).
United States Jan Nolta Thomas Schroeder Emily Henderson Department Of Hematology American Cancer Society

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science